Towards Improved XAI-Based Epidemiological Research into the Next Potential Pandemic.

Publication date: Jun 21, 2024

By applying AI techniques to a variety of pandemic-relevant data, artificial intelligence (AI) has substantially supported the control of the spread of the SARS-CoV-2 virus. Along with this, epidemiological machine learning studies of SARS-CoV-2 have been frequently published. While these models can be perceived as precise and policy-relevant to guide governments towards optimal containment policies, their black box nature can hamper building trust and relying confidently on the prescriptions proposed. This paper focuses on interpretable AI-based epidemiological models in the context of the recent SARS-CoV-2 pandemic. We systematically review existing studies, which jointly incorporate AI, SARS-CoV-2 epidemiology, and explainable AI approaches (XAI). First, we propose a conceptual framework by synthesizing the main methodological features of the existing AI pipelines of SARS-CoV-2. Upon the proposed conceptual framework and by analyzing the selected epidemiological studies, we reflect on current research gaps in epidemiological AI toolboxes and how to fill these gaps to generate enhanced policy support in the next potential pandemic.

Open Access PDF

Concepts Keywords
Basel AI
Enhanced epidemiology
Epidemiology explainable deep learning
Toolboxes explainable machine learning
Virus interpretable deep learning
interpretable machine learning
non-pharmaceutical interventions
SARS-CoV-2

Semantics

Type Source Name
drug DRUGBANK Coenzyme M
disease VO population
disease IDO process
disease IDO blood
drug DRUGBANK Flunarizine
disease MESH uncertainty
disease IDO algorithm
pathway REACTOME Translation
drug DRUGBANK Pidolic Acid
disease VO frequency
disease IDO entity
disease IDO colony
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Saquinavir
disease VO Gap
disease VO efficient
disease VO vaccine
disease VO Optaflu
disease MESH influenza
disease IDO country
disease MESH unemployment
disease VO vaccination
disease VO time
disease VO vaccinated
disease VO URE
drug DRUGBANK Medical air
disease MESH comorbidity
disease MESH death
disease MESH COVID 19
drug DRUGBANK (S)-Des-Me-Ampa
disease VO volume
disease MESH Emergency
drug DRUGBANK Tricyclazole
pathway KEGG Autophagy
drug DRUGBANK Gold
disease MESH critically ill
disease VO USA
drug DRUGBANK Vorinostat
disease MESH pneumonia
drug DRUGBANK Trestolone
disease MESH cardiovascular diseases
drug DRUGBANK Guanosine
disease MESH Infections
disease MESH Cardiac Arrest
disease MESH Complications
disease VO effectiveness
disease MESH Viral Infections
disease MESH Long Covid
disease IDO infection
disease IDO cell
disease VO Canada

Original Article

(Visited 2 times, 1 visits today)